Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study
Alba Sparacino, Gabriele Di Maria, Marco Vaccaro, Giuseppe Cabibbo, Calogero Cammà, María Reig, Robin Kate Kelley, Amit G. Singal, Ahmed O. Kaseb, Masatoshi Kudo, Lorenza Rimassa, David J. Pinato, Ciro Celsa, Tiziana Pressiani, Naoshi Nishida, Shadi Chamseddine, Ashwini Arvind, Michael Li, Marta Fortuny, Najib Ben Khaled, Massimo Iavarone, Hidenori Toyoda, Ilario Giovanni Rapposelli, Andrea Casadei‐Gardini, Caterina Vivaldi, Susanna V. Ulahannan, Haripriya Andanamala, Bernhard Scheiner, Matthias Pinter, Elena Orlandi, Claudia Angela Maria Fulgenzi, Giulia Francesca Manfredi, Pasquale Lombardi, Antonio D’Alessio, Bernardo Stefanini, Rosanna Villani, Francesca Romana Ponziani, Leonardo Stella, Ornella Carminati, Angela Dalia Ricci, Melina Gonzalez (2025). Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study. , 8(3), DOI: https://doi.org/10.1016/j.jhepr.2025.101685.
